X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WYETH LTD ALKEM LABORATORIES/
WYETH LTD
 
P/E (TTM) x - 27.7 - View Chart
P/BV x 7.4 5.3 138.6% View Chart
Dividend Yield % 0.6 1.3 45.9%  

Financials

 ALKEM LABORATORIES   WYETH LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
WYETH LTD
Mar-13
ALKEM LABORATORIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,044 152.1%   
Low Rs1,232818 150.6%   
Sales per share (Unadj.) Rs417.5298.6 139.8%  
Earnings per share (Unadj.) Rs56.357.2 98.3%  
Cash flow per share (Unadj.) Rs64.758.4 110.8%  
Dividends per share (Unadj.) Rs12.7017.00 74.7%  
Dividend yield (eoy) %0.91.8 49.3%  
Book value per share (Unadj.) Rs292.9249.5 117.4%  
Shares outstanding (eoy) m119.5722.72 526.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.1 108.3%   
Avg P/E ratio x25.116.3 154.0%  
P/CF ratio (eoy) x21.815.9 136.7%  
Price / Book Value ratio x4.83.7 129.0%  
Dividend payout %22.629.7 76.0%   
Avg Mkt Cap Rs m168,65321,157 797.2%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m9,171400 2,292.8%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m49,9156,783 735.8%  
Other income Rs m1,645353 466.6%   
Total revenues Rs m51,5617,136 722.5%   
Gross profit Rs m8,4821,617 524.5%  
Depreciation Rs m1,00627 3,781.2%   
Interest Rs m6716 12,192.7%   
Profit before tax Rs m8,4511,938 436.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,606632 254.0%   
Profit after tax Rs m6,7311,301 517.6%  
Gross profit margin %17.023.8 71.3%  
Effective tax rate %19.032.6 58.2%   
Net profit margin %13.519.2 70.3%  
BALANCE SHEET DATA
Current assets Rs m27,0626,984 387.5%   
Current liabilities Rs m15,3242,056 745.3%   
Net working cap to sales %23.572.6 32.4%  
Current ratio x1.83.4 52.0%  
Inventory Days Days6799 67.0%  
Debtors Days Days4124 172.4%  
Net fixed assets Rs m12,610244 5,161.5%   
Share capital Rs m239227 105.2%   
"Free" reserves Rs m34,4905,441 633.9%   
Net worth Rs m35,0275,668 618.0%   
Long term debt Rs m1,21225 4,846.4%   
Total assets Rs m54,3877,901 688.4%  
Interest coverage x13.6353.3 3.8%   
Debt to equity ratio x00 784.2%  
Sales to assets ratio x0.90.9 106.9%   
Return on assets %13.616.5 82.3%  
Return on equity %19.222.9 83.8%  
Return on capital %24.934.0 73.0%  
Exports to sales %12.90.2 5,932.8%   
Imports to sales %3.136.3 8.5%   
Exports (fob) Rs m6,46115 43,656.1%   
Imports (cif) Rs m1,5402,465 62.5%   
Fx inflow Rs m6,56315 43,179.6%   
Fx outflow Rs m3,0122,677 112.5%   
Net fx Rs m3,552-2,662 -133.4%   
CASH FLOW
From Operations Rs m7,259923 786.2%  
From Investments Rs m1,864317 588.3%  
From Financial Activity Rs m-9,273-481 1,927.8%  
Net Cashflow Rs m-150759 -19.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 33.1 11.3 292.9%  
FIIs % 0.0 7.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 30.4 -  
Shareholders   68,381 21,978 311.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 10:29 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - DR. REDDYS LAB COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS